RE:RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer comboAugust 27, 2024 - Bispecific T-cell engagers (BiTEs) are designed to link T-cells to cancer cells by binding to the CD3 receptor on T-cells and a specific antigen on cancer cells. This close proximity induces T-cell activation and the release of cytotoxic molecules, leading to the targeted destruction of cancer cells. This mechanism has been particularly successful in treating certain types of hematologic malignancies, and ongoing research is exploring its potential in solid tumors.
As previously posted, combination therapy and now multispecific antibodies represent a significant advancement in cancer cell targeting, offering new avenues for the treatment of both solid tumors and hematologic malignancies. By engaging multiple antigens and immune pathways, these engineered molecules have the potential to overcome resistance mechanisms and improve patient outcomes. As research continues and more clinical data become available, multispecific antibodies are poised to become a cornerstone of precision oncology, providing targeted and effective treatments for a wide range of cancers.
https://www.biospace.com/press-releases/multispecific-antibodies-in-cancer-cell-targeting